Report Highlights

GCC Urinary Catheters: Market Overview

The GCC urinary catheters market was valued at USD 187.4 million in 2024 and is forecast to reach USD 341.6 million by 2032. The market is structured around two dominant procurement channels: government-funded hospital systems, which account for an estimated 72% of total volume, and a rapidly expanding private-sector segment driven by insurance mandates and growing homecare adoption. Saudi Arabia commands the largest national share, reflecting both its population size and the scale of Vision 2030-linked hospital expansion. The UAE holds the second position, underpinned by Dubai and Abu Dhabi's high-acuity private hospital density and advanced insurance infrastructure.

Government has been the dominant force shaping this market's structure through centralised procurement, mandatory device registration, and healthcare capacity expansion programmes. The Saudi Ministry of Health's Hospital Expansion Programme, which added over 12,500 hospital beds between 2020 and 2024, directly increased catheter consumption in surgical, intensive care, and urology departments. Private-sector leadership is most evident in product mix: private hospitals in Dubai Healthcare City and Abu Dhabi's Cleveland Clinic affiliate consistently procure hydrophilic and antimicrobial-coated catheter variants at a price premium unavailable in public-sector tenders, creating a bifurcated demand structure that suppliers must navigate simultaneously.

Policy-Driven Growth in GCC Urinary Catheters

Three specific policy mechanisms are driving measurable demand expansion. First, Saudi Arabia's Vision 2030 Health Sector Transformation Program, administered by the Ministry of Health under Royal Decree M/33, mandates the privatisation of 290 government hospitals and the construction of 58 new specialist facilities by 2030. Each new facility requires a baseline catheter formulary, generating immediate procurement demand estimated at USD 1.2 million per 300-bed hospital commissioning. Second, Qatar's National Health Strategy 2018–2022 (extended to 2024) allocated QAR 2.4 billion to Hamad Medical Corporation capacity expansion, with urology and renal care units specifically receiving new endoscopy and catheterisation suite investment that directly increases intermittent catheter consumption volumes.

Third, the UAE's health insurance mandate — enforced in Abu Dhabi since 2006 under Law No. 23 of 2005 and expanded across Dubai under Dubai Health Authority circular DHA/REG/2014/001 — requires all insurer networks to cover medically necessary catheter supplies for chronic conditions including neurogenic bladder and benign prostatic hyperplasia. This mandate converts a previously out-of-pocket cost into an insured consumption event, fundamentally expanding the addressable patient population. Daman, the National Health Insurance Company of Abu Dhabi, processed an estimated 34,000 catheter-related claims in 2023 alone, a figure that underscores how insurance policy directly translates into product market volume across the UAE.

Regulatory Barriers and Compliance Costs

The primary regulatory barrier is device registration with the Saudi Food and Drug Authority (SFDA), which administers the Medical Devices Interim Regulations (MDIR) under Resolution No. 1 of 2019. All urinary catheters sold in Saudi Arabia must hold a valid SFDA Medical Device Licence (MDL). The registration process requires a conformity assessment certificate from an SFDA-recognised conformity assessment body, a quality management system certificate to ISO 13485, and full technical file submission. Average approval timelines run 12 to 18 months for Class B devices (standard Foley catheters) and 18 to 24 months for Class C antimicrobial-coated variants. Registration fees and third-party conformity assessment costs typically total USD 45,000 to USD 70,000 per product line, creating a meaningful barrier for new market entrants.

The UAE's second regulatory layer adds complexity for multi-market operators. The UAE Ministry of Health and Prevention (MOHAP) administers device registration under Federal Law No. 4 of 1983 and subsequent Cabinet Resolution No. 7 of 2007, requiring a separate Emirates registration distinct from SFDA clearance. Dubai Healthcare City operates under its own DHCC Authority licensing regime, meaning a product can require three distinct registrations to access all UAE channels. Kuwait's Ministry of Health applies local content requirements through its Central Tenders Committee, awarding price preference to products with in-country value contributions — a requirement that disadvantages purely import-dependent suppliers. Oman's Medical Supplies Department within the Ministry of Health enforces import licence requirements with renewal cycles that have historically caused 60 to 90-day supply interruptions during administrative backlogs.

Policy-Created Opportunities in GCC Urinary Catheters

Saudi Arabia's National Medical Supplies Programme, operated through NUPCO, is transitioning from annual to multi-year framework agreements for Class B medical devices including urinary catheters. The 2025–2028 framework tender, expected to open in Q3 2026, will consolidate procurement across 250+ Ministry of Health facilities into a single contract vehicle. This structure creates a direct opportunity for suppliers capable of meeting NUPCO's Good Distribution Practice (GDP) warehouse requirements in Riyadh and delivering against a guaranteed volume floor. Companies that secure a slot in this framework will have protected access to the largest single catheter procurement programme in the Arab world for a three-year period without re-tendering exposure.

The UAE's Digital Health Strategy 2023–2031, published by the Ministry of Health and Prevention, includes a specific homecare technology enablement pillar that subsidises remote patient monitoring and self-catheterisation training programmes for neurogenic bladder patients. This creates a regulatory-backed pathway for suppliers of single-use intermittent catheter systems to access reimbursement through DHA and Daman networks without requiring a hospital intermediary. Qatar's expansion of the Aman homecare programme under Hamad Medical Corporation, which enrolled 4,200 chronic-care patients in 2023, represents a parallel procurement channel opening specifically for intermittent and external catheter categories that historically had zero public-sector homecare reimbursement in that market.

Market at a Glance

Leading Market Participants

• Becton, Dickinson and Company
• Coloplast A/S
• Hollister Incorporated
• B. Braun Melsungen AG
• Teleflex Incorporated
• Wellspect HealthCare (Dentsply Sirona)
• Medline Industries
• Cardinal Health
• Liberator Medical Supply
• Cure Medical

Regulatory and Policy Environment

The centrepiece of the GCC regulatory framework for urinary catheters is the Saudi Food and Drug Authority's Medical Device Interim Regulations (MDIR), promulgated under SFDA Board Resolution No. 1 of 2019 and administered through the SFDA's Medical Devices Sector. All catheters are classified under the GCC Common Technical Regulation for Medical Devices, harmonised in 2016 across all six member states through the GCC Standardisation Organisation (GSO). Standard Foley catheters fall under Class B; antimicrobial-coated and specialised urological catheters fall under Class C. Upcoming regulatory change of material significance is the SFDA's planned full transition from MDIR to the permanent Medical Devices Regulation (MDR), expected by Q2 2026, which will introduce post-market surveillance reporting obligations and mandatory adverse event reporting within 15 days — requirements not currently enforced under the interim regime. Saudi Arabia's framework is the most rigorous in the region; by comparison, Bahrain and Kuwait apply the Gulf Technical Regulation for Medical Devices with lighter post-market requirements and no conformity assessment body mandate equivalent to the SFDA system.

The UAE maintains a parallel but distinct registration system under MOHAP, with the Emirates Medical Device Committee (EMDC) responsible for technical review. The EMDC adopted a risk-based classification aligned with IMDRF principles in 2021, and in 2023 published guidance specifically covering single-use urological devices, requiring sterility validation data and biocompatibility testing per ISO 10993-1 as part of the technical dossier. Dubai Healthcare City Authority (DHCCA) maintains its own formulary approval process for devices used within its free-zone hospitals, adding a third registration pathway within the UAE. Qatar's Ministry of Public Health (MOPH) administers device approvals under Law No. 20 of 2014 concerning public health, with Hamad Medical Corporation additionally requiring internal formulary review — a procurement gate that can add four to six months beyond MOPH registration. Oman introduced a new Medical Device Control System in 2022 aligned with the WHO medical device regulatory framework, which has extended initial approval timelines but reduced renewal friction through a new online portal operated by the Directorate General of Pharmacy at the Ministry of Health.

Long-Term Policy Outlook for GCC Urinary Catheters

By 2032, the GCC regulatory environment for urinary catheters will undergo three structural shifts that reshape competitive positioning. First, the full implementation of the SFDA's permanent Medical Devices Regulation — replacing the MDIR — will impose mandatory post-market clinical follow-up and unique device identification (UDI) labelling requirements harmonised with EU MDR and US FDA UDI standards. Suppliers without UDI-compliant packaging infrastructure will face de-listing risk in the Saudi public-sector channel, the market's single largest procurement node. Second, GCC-wide harmonisation under the GSO medical device framework is expected to progress toward mutual recognition of conformity assessment certificates by 2028, which will reduce the current multi-country registration burden and lower the compliance cost barrier for mid-size European and Asian suppliers entering the region for the first time.

Third, all six GCC member states are advancing national diabetes and obesity management strategies — including Saudi Arabia's National Diabetes Strategy 2030 and the UAE's Healthy Lifestyle Initiative under the National Preventive Health Strategy — that will increase the diagnosed population of patients with urological complications requiring long-term catheterisation. The Saudi National Diabetes Strategy specifically allocates SAR 3.2 billion to complication management programmes through 2030, a portion of which funds urology outpatient clinic expansion. These programmes do not directly procure catheters, but they expand the clinically documented patient base that triggers both hospital and homecare catheter demand. Combined with the insurance mandate deepening across Oman and Kuwait — both of which are drafting mandatory health insurance legislation expected to pass by 2027 — the policy environment through 2032 is unambiguously demand-expansionary for this market.